Put Options

17 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Jan 18, 2024

BUY
$31.87 - $40.71 $95,610 - $122,130
3,000 New
3,000 $6,000
Q1 2022

Apr 14, 2022

SELL
$51.32 - $68.5 $41,056 - $54,800
-800 Reduced 8.0%
9,200 $1,000
Q4 2021

Jan 18, 2022

SELL
$47.03 - $57.12 $1.06 Million - $1.29 Million
-22,500 Reduced 69.23%
10,000 $78,000
Q3 2021

Oct 26, 2021

SELL
$52.17 - $70.2 $391,275 - $526,500
-7,500 Reduced 18.75%
32,500 $787,000
Q2 2021

Jul 19, 2021

BUY
$68.86 - $83.34 $241,010 - $291,690
3,500 Added 9.59%
40,000 $556,000
Q1 2021

Apr 26, 2021

BUY
$76.15 - $111.94 $2.21 Million - $3.25 Million
29,000 Added 386.67%
36,500 $427,000
Q4 2020

Jan 21, 2021

BUY
$96.85 - $148.25 $668,265 - $1.02 Million
6,900 Added 1150.0%
7,500 $70,000
Q2 2020

Jul 22, 2020

SELL
$185.52 - $231.25 $259,728 - $323,750
-1,400 Reduced 70.0%
600 $17,000
Q4 2019

Feb 06, 2020

SELL
$146.12 - $215.82 $263,016 - $388,476
-1,800 Reduced 47.37%
2,000 $0
Q3 2019

Oct 28, 2019

BUY
$130.44 - $187.64 $182,616 - $262,696
1,400 Added 58.33%
3,800 $9,000
Q2 2019

Aug 09, 2019

BUY
$111.45 - $128.93 $256,335 - $296,539
2,300 Added 2300.0%
2,400 $9,000
Q4 2018

Feb 05, 2019

SELL
$87.81 - $110.65 $122,934 - $154,910
-1,400 Reduced 93.33%
100 $0
Q3 2018

Nov 07, 2018

BUY
$90.63 - $120.22 $18,126 - $24,044
200 Added 15.38%
1,500 $5,000
Q2 2018

Aug 10, 2018

SELL
$88.4 - $105.34 $79,560 - $94,806
-900 Reduced 40.91%
1,300 $21,000
Q1 2018

May 11, 2018

BUY
$94.51 - $120.23 $122,863 - $156,299
1,300 Added 144.44%
2,200 $26,000
Q4 2017

Jan 17, 2018

SELL
$84.48 - $104.02 $202,752 - $249,648
-2,400 Reduced 72.73%
900 $10,000
Q3 2017

Oct 17, 2017

BUY
$73.17 - $103.47 $241,461 - $341,451
3,300
3,300 $1,000

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.85B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.